ASIC launched legal action against QBE in October, alleging it misled half a million Aussies over insurance loyalty discounts. Then the QBE stock price surged.
Dale Gillham
 | Dale Gillham is chief investment analyst at Wealth Within Limited (AFSL 226347). He also serves as the head trainer at the Wealth Within Institute (RTO 21917). He has more than three decades of experience in the investment industry, and is the author of How to Beat the Managed Funds by 20%, Dale's qualifications include an Advanced Diploma and a Diploma of Share Trading and Investment. He co-hosts the Talking Wealth Podcast, and his work has appeared in The Australian Financial Review, New York Business Journal, Wall Street Select and more. |
198 results for Dale Gillham:
Woolworths is grappling with a perfect storm - strikes at its distribution centres have caused empty shelves, frustrated shoppers, and a jaw-dropping $50 million sales hit.
Pro Medicus, Lendlease and Telix Pharmaceuticals were among the best performers on the ASX top 100 this week.
What stocks should you be adding to your Christmas list? Dale Gillham joins Tom Watson on the Friends With Money podcast.
What does the merger between Sigma Healthcare and Chemist Warehouse mean for you - greater access to cheaper medicines or the loss of community pharmacies?
With Donald Trump focused on boosting US energy independence, American energy exports could shrink, leaving room for Australia to step in and fill global demand.
Microcaps are companies with a market capitalisation of less than $500 million, so what are the top five microcaps on the ASX?
With defence spending forecast to rise in the coming years, which ASX-listed companies could be set to benefit?
Now could be the right time for you to take a closer look at some of the biggest players in the Australian energy sector.
Did Rio Tinto overpay with its $9.9 billion acquisition of Arcadium Lithium, or could this bold move be one of the best deals we've seen in recent times?
